Alumis to Participate in Upcoming November Investor Conferences

Rhea-AI Summary

Alumis (Nasdaq: ALMS) will participate in two investor conferences in November 2025: Guggenheim Healthcare Innovation Conference in Boston (Nov 10-12) with a fireside chat on Nov 11, 2025 at 1:30 PM ET, and the Stifel 2025 Healthcare Conference in New York (Nov 11-13) with a presentation on Nov 12, 2025 at 2:00 PM ET.

Live webcasts will be available via the company’s Investors > Events page, and replay archives will remain on the website for 90 days.

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences:

• Guggenheim’s 2^nd Annual Healthcare Innovation Conference
  November 10-12, 2025, Boston, MA
  Fireside chat: Tuesday, November 11, 2025 at 1:30 pm ET

• Stifel 2025 Healthcare Conference
  November 11-13, 2025, New York, NY
  Presentation: Wednesday, November 12, 2025 at 2:00 pm ET

To access the live webcasts please visit the “Events” page of the “Investors" section of the Alumis website. Webcast replays will be archived on the company's website for 90 days.

About Alumis
Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib, formerly known as ESK-001, for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, the pipeline includes lonigutamab, a subcutaneously delivered anti–insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach. For more information, visit www.alumis.com or follow us on LinkedIn or X.

Forward Looking Statements
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements regarding Alumis’ participation at upcoming conferences. Alumis explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Alumis Contact Information
Teri Dahlman
Red House Communications
teri@redhousecomms.com

FAQ

When will Alumis (ALMS) present at Guggenheim’s Healthcare Innovation Conference?

Alumis will hold a fireside chat on November 11, 2025 at 1:30 PM ET during Guggenheim’s conference in Boston.

What time is the Alumis (ALMS) presentation at the Stifel 2025 Healthcare Conference?

The Alumis presentation is scheduled for November 12, 2025 at 2:00 PM ET in New York.

How can investors watch the Alumis (ALMS) webcasts for the November 2025 conferences?

Investors can access live webcasts on the company’s Investors > Events page; replays will be archived on the website for 90 days.

Will Alumis (ALMS) provide replay access for conference presentations and for how long?

Yes. Webcast replays will be archived on the company website and available for 90 days after the events.

Which dates should shareholders mark for Alumis (ALMS) investor events in November 2025?

Key dates are November 11, 2025 (Guggenheim fireside chat) and November 12, 2025 (Stifel presentation).

Where will Alumis (ALMS) be presenting during the week of November 10–13, 2025?

Alumis will present at the Guggenheim Healthcare Innovation Conference in Boston and the Stifel 2025 Healthcare Conference in New York.